Search｜Photos & Images & Videos｜KYODO NEWS IMAGES INC

Press Conference in Front of Sanofi Gentilly Against the Closure of The Site

Illustration Sanofi logo. Rally and press briefing against the closure of the Sanofi site in Gentilly. Mayor Fatah Aggoune had called on all elected representatives to support the mobilization, along with the CGT union. Gentilly, Val-de-Marne, France, November 15, 2024. Photo by Karim Ait Adjedjou/ABACAPRESS.COM

E

Press Conference in Front of Sanofi Gentilly Against the Closure of The Site

Illustration Sanofi logo. Rally and press briefing against the closure of the Sanofi site in Gentilly. Mayor Fatah Aggoune had called on all elected representatives to support the mobilization, along with the CGT union. Gentilly, Val-de-Marne, France, November 15, 2024. Photo by Karim Ait Adjedjou/ABACAPRESS.COM

E

Press Conference in Front of Sanofi Gentilly Against the Closure of The Site

Rally and press briefing against the closure of the Sanofi site in Gentilly. Mayor Fatah Aggoune had called on all elected representatives to support the mobilization, along with the CGT union. Gentilly, Val-de-Marne, France, November 15, 2024. Photo by Karim Ait Adjedjou/ABACAPRESS.COM

E

French Minister for the Economy Visits Sanofi - Lisieux - France

French Minister for the Economy, Finance and Industry Antoine Armand and French Deputy Minister for Industry Marc Ferracci visits the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

French Minister for the Economy Visits Sanofi - Lisieux - France

French Minister for the Economy, Finance and Industry Antoine Armand and French Deputy Minister for Industry Marc Ferracci visits the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

French Minister for the Economy Visits Sanofi - Lisieux - France

French Minister for the Economy, Finance and Industry Antoine Armand and French Deputy Minister for Industry Marc Ferracci visits the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

French Minister for the Economy Visits Sanofi - Lisieux - France

French Minister for the Economy, Finance and Industry Antoine Armand and Sanofi's Chairman of the board of directors Frédéric Oudéawith during the official visit of the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

French Minister for the Economy Visits Sanofi - Lisieux - France

French Deputy Minister for Industry Marc Ferracci visits the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

French Minister for the Economy Visits Sanofi - Lisieux - France

Sanofi's Chairman of the board of directors Frédéric Oudéa welcomes French Minister for the Economy, Finance and Industry Antoine Armand and French Deputy Minister for Industry Marc Ferracci in the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

French Minister for the Economy Visits Sanofi - Lisieux - France

French Deputy Minister for Industry Marc Ferracci visits the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

French Minister for the Economy Visits Sanofi - Lisieux - France

French Minister for the Economy, Finance and Industry Antoine Armand with employees as he visits the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

French Minister for the Economy Visits Sanofi - Lisieux - France

Fench Minister for the Economy, Finance and Industry Antoine Armand visits the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

French Minister for the Economy Visits Sanofi - Lisieux - France

French Minister for the Economy, Finance and Industry Antoine Armand and French Deputy Minister for Industry Marc Ferracci with employeesas as they visit the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

French Minister for the Economy Visits Sanofi - Lisieux - France

French Minister for the Economy, Finance and Industry Antoine Armand and Sanofi's Chairman of the board of directors Frédéric Oudéawith during the official visit of the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

French Minister for the Economy Visits Sanofi - Lisieux - France

Fench Minister for the Economy, Finance and Industry Antoine Armand visits the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

French Minister for the Economy Visits Sanofi - Lisieux - France

Sanofi's Chairman of the board of directors Frédéric Oudéa welcomes French Minister for the Economy, Finance and Industry Antoine Armand and French Deputy Minister for Industry Marc Ferracci in the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

French Minister for the Economy Visits Sanofi - Lisieux - France

Sanofi's Chairman of the board of directors Frédéric Oudéa welcomes French Minister for the Economy, Finance and Industry Antoine Armand and French Deputy Minister for Industry Marc Ferracci in the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

French Minister for the Economy Visits Sanofi - Lisieux - France

French Deputy Minister for Industry Marc Ferracci visits the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

French Minister for the Economy Visits Sanofi - Lisieux - France

French Minister for the Economy, Finance and Industry Antoine Armand with employees as he visits the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

French Minister for the Economy Visits Sanofi - Lisieux - France

French Minister for the Economy, Finance and Industry Antoine Armand with employees as he visits the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

French Minister for the Economy Visits Sanofi - Lisieux - France

Fench Minister for the Economy, Finance and Industry Antoine Armand visits the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

French Minister for the Economy Visits Sanofi - Lisieux - France

French Minister for the Economy, Finance and Industry Antoine Armand with employees as he visits the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

French Minister for the Economy Visits Sanofi - Lisieux - France

French Minister for the Economy, Finance and Industry Antoine Armand with employees as he visits the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

French Minister for the Economy Visits Sanofi - Lisieux - France

French Minister for the Economy, Finance and Industry Antoine Armand with employees as he visits the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

French Minister for the Economy Visits Sanofi - Lisieux - France

French Minister for the Economy, Finance and Industry Antoine Armand as he visits the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

French Minister for the Economy Visits Sanofi - Lisieux - France

French Minister for the Economy, Finance and Industry Antoine Armand and French Deputy Minister for Industry Marc Ferracci with employeesas as they visit the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

French Minister for the Economy Visits Sanofi - Lisieux - France

French Minister for the Economy, Finance and Industry Antoine Armand and French Deputy Minister for Industry Marc Ferracci with employeesas as they visit the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM